Shanghai, February 10, 2022 – Sperogenix Therapeutics, a biopharma dedicated to developing and commercializing rare disease therapeutics in China and Luca Healthcare, China’s category leader in developing and maintaining regulated and clinically validated digital health solutions, today announced a strategic partnership to develop digital therapeutics for Sperogenix’s pipeline of rare disease treatments and improve overall treatment benefits.
Leveraging Luca’s platform of patient-centric tools and portfolio of digital biomarkers, these smartphone-based companion applications will help patients manage their complex conditions and provide education and guidance in therapy administration with the goal to enhance patients’ healthcare experiences and overall outcomes. The first digital companion products will utilize Luca’s neuromotor tools, sound-based biomarkers and wearable devices to support Sperogenix’s therapies in neuromuscular rare diseases, such as Myasthenia Gravis (“MG”), Duchenne muscular dystrophy (“DMD”), and inherited disorders such Adrenoleukodystrophy(“ALD”).
“We are delighted to enter into this partnership with Luca to offer support to our rare disease patients. We believe digital therapeutics are an opportunity for us to increase effectiveness in the way patients use our medications and improve the overall safety and healthcare outcome,” said Alan Yan, Co-founder, Chairman and CEO of Sperogenix Therapeutics. “We expect to deploy these applications to help patients manage their conditions, improve adherence and any escalations.”
“China has over 20 million rare disease patients. Each disease has a very complex set of conditions and symptoms to manage. Our simple-to-use, medical-grade mini-programs and apps can significantly enhance the patients’ quality of life,” said Echo Chen, Ph.D., CEO of Luca Healthcare. “Luca’s clinically validated tools can meaningfully improve care across a wide range of diseases in homes and other non-clinical settings. We are thrilled to be working with Sperogenix to support their patients in their journey to manage their health.”
Sperogenix Therapeutics is a platform company dedicated to developing and commercializing rare disease therapeutics in China. With prioritized therapeutic areas, such as pulmonary vascular disorders, neuromuscular diseases, and inherited metabolic diseases, Sperogenix is dedicated to establishing an innovative commercial model tailored to the China rare disease field in order to provide affordable and reliable products and services to Chinese physicians and patients. Sperogenix was founded in 2019 and is backed by biopharma industry blue chip investors including Lilly Asia Ventures and Morningside Ventures. www.sperogenix.com